Development and validation of LC–MS/MS method for quantitation of sodium oligomannate in human plasma, urine and feces

Sodium oligomannate was approved for marketing by the National Medical Products Administration of China in 2019 for improving cognitive functions in mild-to-moderate Alzheimer's disease patients. LC–MS/MS methods were established and validated for the quantitation of sodium oligomannate in huma...

Full description

Saved in:
Bibliographic Details
Published in:Bioanalysis 2023-04, Vol.15 (7), p.371-390
Main Authors: Zhang, Zhenqing, Yang, Xing, Zhang, Lu, Zhu, Haizhong, Huang, Biao, Chen, Qian, Wang, Yijun, Yu, Chen, Bi, Luke, Geng, Meiyu, Li, Liang
Format: Article
Language:English
Subjects:
Alzheimer's disease
excretion
LC–MS/MS
pharmacokinetics
phase I clinical trial
sodium oligomannate
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sodium oligomannate was approved for marketing by the National Medical Products Administration of China in 2019 for improving cognitive functions in mild-to-moderate Alzheimer's disease patients. LC–MS/MS methods were established and validated for the quantitation of sodium oligomannate in human plasma, urine and feces to support clinical development studies. Samples were prepared using liquid–liquid extraction and analyzed by ion-pair reversed-phase LC–MS/MS with calibration standard curve ranges of 25.0–5000 ng/ml, 0.500–100 μg/ml and 100–10,000 μg/g in plasma, urine and feces, respectively. All validation parameters met the respective acceptance criteria established by US FDA and International Council for Harmonisation of Technical Requirements for Human Use guidelines. The validated methods were applied to a pharmacokinetics and excretion study in healthy Chinese subjects.
ISSN:1757-6180
1757-6199
DOI:10.4155/bio-2023-0026